Value of lactate level in predicting the short-term prognosis of patients with acute-on-chronic hepatitis B liver failure

Shuo YANG; Kun LIU; Lan YANG; Ling XU; Xiaobo LU; Xiaofeng SUN; MALIPATI Elkenjiang

doi:10.3969/j.issn.1001-5256.2022.07.007

Volume 38 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(7): 1482-1488

PDF( 2603 KB)

Value of lactate level in predicting the short-term prognosis of patients with acute-on-chronic hepatitis B liver failure

DOI: 10.3969/j.issn.1001-5256.2022.07.007

Shuo YANG^1a,
Kun LIU^1b,
Lan YANG^1b,
Ling XU^1b,
Xiaobo LU^{1a, 2},
Xiaofeng SUN^{1a, 2
,
,
,},
MALIPATI Elkenjiang^1b

1a.
Center for Infectious Diseases-Hepatology of The First Affiliated Hospital, Xinjiang Medical University, Urumqi 830000, China
1b.
The First Clinical Medical College, Xinjiang Medical University, Urumqi 830000, China
2.
Xinjiang Clinical Medical Research Center for Infectious Diseases (Viral Hepatitis), Urumqi 830000, China

Research funding:

National Natural Science Foundation of China (82060115)

More Information

Corresponding author: SUN Xiaofeng, xjwlsxf@163.com(ORCID: 0000-0002-2596-3669)
Received Date: 2021-12-06
Accepted Date: 2022-01-22
Published Date: 2022-07-20

Abstract

Abstract

Objective To investigate the value of lactate in predicting the 90-day prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Methods A retrospective analysis was performed for 117 patients with HBV-ACLF who were admitted to Center for Infectious Diseases-Hepatology, The First Affiliated Hospital of Xinjiang Medical University, from January 2017 to June 2021, and according to the results of 90-day follow-up, they were divided into survival group with 43 patients and death group with 74 patients. Related clinical data were collected, including routine blood test results, hepatic and renal function, coagulation function, arterial blood gas parameters, and complications such as hepatic encephalopathy within 24 hours after the diagnosis of HBV-ACLF in our hospital, and albumin-bilirubin (ALBI), Model for End-Stage Liver Disease (MELD), MELD combined with serum sodium concentration (MELD-Na), MELD to SNa ratio (MESO), integrated MELD (iMELD), and CLIF-C ACLF scores were calculated. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups. A binary logistic regression analysis was used to investigate whether lactate was an independent risk factor for the 90-d prognosis of HBV-ACLF patients, and a Pearson correlation analysis was used to investigate the correlation of lactate with infection and clinical complications. The receiver operating characteristic (ROC) curve was plotted to analyze whether lactate, in combination with each score, can improve the predictive value of the existing model, and the Z test was used for pairwise comparison. Results Compared with the survival group, the death group had significantly higher white blood cell count, international normalized ratio (INR), and lactate and a significantly lower level of Na (Z=-2.813, -2.855, and -3.186, and -2.044, all P < 0.05), as well as significantly higher age and MELD, MELD-Na, MESO, iMELD, and CLIF-C ACLF scores (t=2.536, 4.615, 4.247, 4.941, 5.832, and 7.562, all P < 0.05). The logistic regression analysis showed that age (odds ratio [OR]=1.075, 95% confidence interval [CI]: 1.026-1.127, P=0.002), INR (OR=2.198, 95%CI: 1.149-4.203, P=0.017), and lactate (OR=1.431, 95%CI: 1.002-2.044, P=0.049) were independent risk factors for the 90-day prognosis of patients with HBV-ACLF, and there was an increase in the area under the ROC curve after lactate was included in the existing models. Conclusion Lactate is an independent risk factor for the 90-day prognosis of patients with HBV-ACLF, and its inclusion in existing models may improve predictive value.
- Acute-on-Chronic Liver Failure,
- Hepatitis B virus,
- Lactic Acid,
- Prognosis

FullText(HTML)

References(38)

References

[1]	BERNAL W, JALAN R, QUAGLIA A, et al. Acute-on-chronic liver failure[J]. Lancet, 2015, 386(10003): 1576-1587. DOI: 10.1016/S0140-6736(15)00309-8.
[2]	LIAW YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia[J]. J Hepatol, 2009, 51(2): 403-410. DOI: 10.1016/j.jhep.2009.04.003.
[3]	SHEN Y, WANG X, ZHANG S, et al. A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics[J]. Sci Rep, 2016, 6: 33389. DOI: 10.1038/srep33389.
[4]	CHEN W, YOU J, CHEN J, et al. Combining the serum lactic acid level and the lactate clearance rate into the CLIF-SOFA score for evaluating the short-term prognosis of HBV-related ACLF patients[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(6): 483-489. DOI: 10.1080/17474124.2020.1763172.
[5]	CHEN W, YOU J, CHEN J, et al. Modified model for end-stage liver disease improves short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2017, 23(40): 7303-7309. DOI: 10.3748/wjg.v23.i40.7303.
[6]	van HALL G. Lactate kinetics in human tissues at rest and during exercise[J]. Acta Physiol(Oxf), 2010, 199(4): 499-508. DOI: 10.1111/j.1748-1716.2010.02122.x.
[7]	NIE Y, ZHANG Y, LIU LX, et al. Serum lactate level predicts short-term and long-term mortality of HBV-ACLF patients: a prospective study[J]. Ther Clin Risk Manag, 2020, 16: 849-860. DOI: 10.2147/TCRM.S272463.
[8]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[9]	JOHNSON PJ, BERHANE S, KAGEBAYASHI C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151.
[10]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
[11]	BIGGINS SW, KIM WR, TERRAULT NA, et al. Evidence-based incorporation of serum sodium concentration into MELD[J]. Gastroenterology, 2006, 130(6): 1652-1660. DOI: 10.1053/j.gastro.2006.02.010.
[12]	HUO TI, WANG YW, YANG YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis[J]. Liver Int, 2007, 27(4): 498-506. DOI: 10.1111/j.1478-3231.2007.01445.x.
[13]	LUCA A, ANGERMAYR B, BERTOLINI G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis[J]. Liver Transpl, 2007, 13(8): 1174-1180. DOI: 10.1002/lt.21197.
[14]	HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
[15]	REN Y, LIU L, LI Y, et al. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B[J]. Hepatol Res, 2018, 48(9): 692-700. DOI: 10.1111/hepr.13062.
[16]	ZHANG WJ, ZHANG LJ, WU JZ. Value of MELD、AARC、COSSH ccoring systems in evaluating the 90 -day prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021. 张文佳, 赵丽娟, 吴基洲. MELD、AARC、COSSH评分系统对乙型肝炎相关慢加急性肝衰竭90天预后的评估价值[J]. 临床肝胆病杂志, 2020, 36(4): 813-817. DOI: 10.3969/j.issn.1001-5256.2020.04.021.
[17]	DU Q, LU SJ, LU DX, et al. Clinical characteristics and prognosis of patients with decompensated liver cirrhosis complicated with chronic and acute liver failure[J]. Chin J Gerontol, 2021, 41(3): 520-523. DOI: 10.3969/j.issn.1005-9202.2021.03.021. 杜蔷, 陆盛菊, 卢大秀, 等. HBV感染失代偿期肝硬化并发慢加急性肝衰竭患者的临床特点及预后[J]. 中国老年学杂志, 2021, 41(3): 520-523. DOI: 10.3969/j.issn.1005-9202.2021.03.021.
[18]	SHANG DB, XIANG XG. Advances in the pathogenesis and treatment of acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(4): 765-769. DOI: 10.3969/j.issn.1001-5256.2021.04.005. 尚大宝, 项晓刚. 慢加急性肝衰竭的发病机制和治疗进展[J]. 临床肝胆病杂志, 2021, 37(4): 765-769. DOI: 10.3969/j.issn.1001-5256.2021.04.005.
[19]	KRAUT JA, MADIAS NE. Lactic acidosis[J]. N Engl J Med, 2014, 371(24): 2309-2319. DOI: 10.1056/NEJMra1309483.
[20]	HILL AV. Muscular activity and carbohydrate metabolism[J]. Science, 1924, 60(1562): 505-514. DOI: 10.1126/science.60.1562.505.
[21]	BROOKS GA. The science and translation of lactate shuttle theory[J]. Cell Metab, 2018, 27(4): 757-785. DOI: 10.1016/j.cmet.2018.03.008.
[22]	CARDOSO FS, ABRALDES JG, SY E, et al. Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure[J]. Liver Int, 2019, 39(7): 1271-1280. DOI: 10.1111/liv.14083.
[23]	KRUSE JA, ZAIDI SA, CARLSON RW. Significance of blood lactate levels in critically ill patients with liver disease[J]. Am J Med, 1987, 83(1): 77-82. DOI: 10.1016/0002-9343(87)90500-6.
[24]	JEPPESEN JB, MORTENSEN C, BENDTSEN F, et al. Lactate metabolism in chronic liver disease[J]. Scand J Clin Lab Invest, 2013, 73(4): 293-299. DOI: 10.3109/00365513.2013.773591.
[25]	DROLZ A, HORVATITS T, RUTTER K, et al. Lactate improves prediction of short-term mortality in critically ill patients with cirrhosis: a multinational study[J]. Hepatology, 2019, 69(1): 258-269. DOI: 10.1002/hep.30151.
[26]	CHAMULEAU RA. Bioartificial liver support anno 2001[J]. Metab Brain Dis, 2002, 17(4): 485-491. DOI: 10.1023/a:1021990725508.
[27]	TRIANTAFYLLOU E, WOOLLARD KJ, MCPHAIL M, et al. The role of monocytes and macrophages in acute and acute-on-chronic liver failure[J]. Front Immunol, 2018, 9: 2948. DOI: 10.3389/fimmu.2018.02948.
[28]	ZHANG DJ, ZHOU B, HOU JL. Research progress in prognostic models of acute-on-chronic liver failure[J]. J Clini Hepatol, 2018, 34(6): 1351-1356. DOI: 10.3969/j.issn.1001-5256.2018.06.047. 张东敬, 周彬, 侯金林. 慢加急性肝衰竭预后模型的研究进展[J]. 临床肝胆病杂志, 2018, 34(6): 1351-1356. DOI: 10.3969/j.issn.1001-5256.2018.06.047.
[29]	LI H, ZHENG J, CHEN L, et al. The scoring systems in predicting short-term outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Ann Palliat Med, 2020, 9(5): 3048-3058. DOI: 10.21037/apm-20-608.
[30]	WILLIAMS MA, BEVAN MJ. Effector and memory CTL differentiation[J]. Annu Rev Immunol, 2007, 25: 171-192. DOI: 10.1146/annurev.immunol.25.022106.141548.
[31]	WHERRY EJ, AHMED R. Memory CD8 T-cell differentiation during viral infection[J]. J Virol, 2004, 78(11): 5535-5545. DOI: 10.1128/JVI.78.11.5535-5545.2004.
[32]	MICHALEK RD, RATHMELL JC. The metabolic life and times of a T-cell[J]. Immunol Rev, 2010, 236: 190-202. DOI: 10.1111/j.1600-065X.2010.00911.x.
[33]	JACOBS SR, HERMAN CE, MACIVER NJ, et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways[J]. J Immunol, 2008, 180(7): 4476-4486. DOI: 10.4049/jimmunol.180.7.4476.
[34]	RATHMELL JC, ELSTROM RL, CINALLI RM, et al. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma[J]. Eur J Immunol, 2003, 33(8): 2223-2232. DOI: 10.1002/eji.200324048.
[35]	VELLINGA N, BOERMA EC, KOOPMANS M, et al. Mildly elevated lactate levels are associated with microcirculatory flow abnormalities and increased mortality: a microSOAP post hoc analysis[J]. Crit Care, 2017, 21(1): 255. DOI: 10.1186/s13054-017-1842-7.
[36]	BAKKER J, NIJSTEN MW, JANSEN TC. Clinical use of lactate monitoring in critically ill patients[J]. Ann Intensive Care, 2013, 3(1): 12. DOI: 10.1186/2110-5820-3-12.
[37]	JEPPESEN JB, MORTENSEN C, BENDTSEN F, et al. Lactate metabolism in chronic liver disease[J]. Scand J Clin Lab Invest, 2013, 73(4): 293-299. DOI: 10.3109/00365513.2013.773591.
[38]	BOSOI CR, ROSE CF. Elevated cerebral lactate: Implications in the pathogenesis of hepatic encephalopathy[J]. Metab Brain Dis, 2014, 29(4): 919-925. DOI: 10.1007/s11011-014-9573-9.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	宋倩，廖盛涛，吕琳，李传飞，梅浙川. 血乳酸水平在肝功能衰竭患者疗效中的研究进展. 现代医药卫生. 2024(07): 1204-1208+1213 .
2.	朱玥洁，李敏，于明凯，何月月，谢忻汝，张峰波，丁剑冰，鲁晓擘. 巨噬细胞及其细胞因子在HBV相关慢加急性肝衰竭患者短期预后中的临床价值分析. 新疆医科大学学报. 2023(02): 153-158+164 .
3.	吴悦嘉，谢青，刘玉盒，陈小勇，闫雪华. 乙型肝炎病毒相关慢加急性肝衰竭评分模型及检验参数对诊断及预后影响的研究进展. 世界华人消化杂志. 2023(06): 207-213 .
4.	刘玉琴，陈密，唐兰燕，周丽智，黄鑫，张磐. 脑乳酸水平与肝性脑病的关系. 临床肝胆病杂志. 2023(07): 1728-1733 . 本站查看